EUCTR2005-001621-29-DE进行中（未招募）1 期
Pre-POINT (Primary Oral INsulin Trial) study A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes - Pre-POINT
Faculty of Medicine Carl Gustav Carus, University of Technology, Dresden0 个研究点目标入组 25 人开始时间: 2007年12月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Children aged 2 years to 7 years who:
- •A. have a multiplex first degree family history of T1DM
- •(both parents, parent and sib, or two sibs);
- •and a type 1 diabetes susceptible HLA DR4-DQB1*0302 or
- •DR4-DQB1*0304 haplotype and none of the following HLA
- •DR or DQB1 alleles:
- •DR7-DQB1*0303
- •DR14-DQB1*0503
- •B. have a sibling with T1DM;
- •and are identical by descent for the HLA DR3/DR4-DQ8 genotype with their
- •diabetic sibling;
- •2. Islet autoantibody negative at time of recruitment.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 25
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Children with any kind of congenital or acquired chronic disease that
- •potentially interfere with the study objectives.
- •2. Prior or current participation in another intervention trial.
- •3. Chronic oral steroid use and/or other chronic oral immunosuppressant
研究者
相似试验
进行中（未招募）
不适用
Pre-POINT (Primary Oral/intranasal INsulin Trial) study A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes - Pre-POINTpre-type 1 diabetes (islet autoimmunity in non-diabetic relatives of subjects with type 1 diabetes)EUCTR2005-001621-29-ATFaculty of Medicine Carl Gustav Carus, University of Technology, Dresden40
尚未招募
不适用
A Pilot Study To Clinically Evaluate InsuPress Wearable Injector In Patients With Type-I/II DiabetesCTRI/2022/06/043064Mediscient Devices OPC Pvt Ltd
已完成
不适用
Early Diabetes Intervention TrialImpaired glucose toleranceNutritional, Metabolic, EndocrineDiabetesISRCTN96631607Bayer plc and Merck-Lipha (UK)631
进行中（未招募）
不适用
A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinomaPatients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinomaMedDRA version: 14.1Level: LLTClassification code 10014745Term: Endometrial carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024396-12-ITOVARTIS FARMA140
进行中（未招募）
1 期
BKM120 as second-line therapy in advanced endometrial cancerEUCTR2010-022015-19-BEovartis Pharma Services AG161